Posted by Michael Wonder on 15 Mar 2022
Single dose Kozenis (tafenoquine) approved for children with Plasmodium vivax malaria by Australian Therapeutic Goods Administration
14 March 2022 - Novel paediatric relapse prevention treatment marks a major contribution towards malaria elimination efforts.
Medicines for Malaria Venture today announces that the Australian TGA has approved the use of single dose Kozenis (tafenoquine) in children aged 2 years and above in combination with chloroquine for the radical cure (prevention of relapse) of Plasmodium vivax malaria.
